FDA Panel Cancels HIV Drug Meeting

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

ROCKVILLE, Md-The FDA has postponed a meeting of its Antiviral Drugs Advisory Committee that was to consider Rescriptor (delavirdine), a Pharmacia and Upjohn Co. drug for use in treating HIV infection. The agency said the postponement will allow time to incorporate results of additional study information that recently became available. The FDA said it will reschedule the meeting, but announced no date.

ROCKVILLE, Md—The FDA has postponed a meeting of its Antiviral Drugs Advisory Committee that was to consider Rescriptor (delavirdine), a Pharmacia and Upjohn Co. drug for use in treating HIV infection. The agency said the postponement will allow time to incorporate results of additional study information that recently became available. The FDA said it will reschedule the meeting, but announced no date.

Related Videos
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Related Content